At the completion of this educational session, participants should be able to:
- Understand the current approach to the diagnosis and staging of hepatitis C virus (HCV) infection.
- Know how HIV/HCV coinfection affects HCV pathogenesis.
- Appreciate treatment outcomes and side effect management to pegylated interferon and ribavirin in both
HCV monoinfected and HIV/HCV coinfected individuals.
Andrew Talal is Associate Professor of Medicine and Associate Medical Director at the Center for the Study of Hepatitis C at the Weill Cornell Medical College. Following his
research fellowship in Gastrointestinal Epidemiology at the University of North Carolina at Chapel Hill, Dr Talal became a Rockefeller University Clinical Scholar in the laboratory of Dr. David Ho where he investigated the pathogenesis of HIV in the gut associated lymphoid tissue. In February 2000, Dr Talal joined the faculty at Weill Cornell where he founded the Viral Hepatitis Clinic, the Center’s Translational Research Laboratory. His research interests include investigation of chemokines as mediators of fibrogenesis and noninvasive biomarkers of hepatic fibrosis. He also has been interested in HCV management in disenfranchised populations including HIV/HCV coinfected and those on opiate agonist therapy.
To obtain CME credit for this and other PRN programs, please visit the PRN Video Channel
at the Clinical Education Initiative (CEI) web site http://www.ceitraining.org/prn-video/. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.